Halobetasol Propionate 0.01%

Introduction Overview

Generic Name

halobetasol propionate 0.01%

Brand Name

Bryhali

Dosage Form

topical lotion

Drug Class

topical corticosteroids (high-potency, Class I)

Pharmacokinetics

Absorption

Halobetasol propionate applied as a topical lotion is absorbed through the skin, where its absorption is influenced by the thickness and condition of the skin barrier, application site, occlusion, and duration of use. Bryhali lotion's lower 0.01% concentration compared to other halobetasol formulations limits systemic absorption; however, absorption can still occur, particularly when applied over large surface areas, under occlusion, or on compromised skin. Due to its potent nature, even small systemic absorption may produce measurable hypothalamic-pituitary-adrenal (HPA) axis suppression in sensitive individuals, necessitating duration-limited use generally not exceeding two weeks.

Distribution

Following cutaneous absorption, halobetasol distributes primarily within the skin, exerting localized anti-inflammatory effects. If systemically absorbed, halobetasol binds variably to plasma proteins, distributing to various tissues. However, systemic plasma concentrations are generally low due to minimal transdermal absorption under recommended use conditions. Distribution is influenced by skin integrity and regional blood flow at the application site. Because of its lipophilic nature, halobetasol concentrates in skin layers providing prolonged local activity.

Metabolism

Halobetasol propionate undergoes rapid metabolism primarily in the skin by hydrolysis and enzymatic degradation. Any systemic halobetasol absorbed is extensively metabolized by hepatic cytochrome P450 enzymes via hydroxylation and conjugation pathways to inactive metabolites. The metabolism reduces systemic exposure and potential toxicity. Metabolic capacity may be altered in patients with significant liver impairment, potentially affecting systemic clearance.

Elimination

Systemically absorbed halobetasol and its metabolites are eliminated mainly via the renal route through urinary excretion of conjugates, with minor fecal elimination through biliary excretion. The elimination half-life following topical application has not been extensively characterized due to low systemic absorption; however, systemic corticosteroids typically exhibit elimination half-lives ranging from hours to days. The reversible nature of HPA axis suppression suggests that halobetasol systemic effects dissipate upon cessation of use.

Dosage Forms

Adults

Bryhali is supplied as a 0.01% halobetasol propionate lotion intended for topical application in adults. The recommended dosing is once daily application of a thin layer to affected areas of plaque psoriasis. Treatment duration should not exceed 8 weeks, with many clinicians recommending a treatment course up to 2 weeks due to potency and risk of HPA axis suppression, followed by assessment. Maximum weekly usage should not exceed 50 grams to mitigate systemic toxicity risks.

Adolescents

Bryhali is not approved for use in individuals under 18 years old due to increased susceptibility to systemic corticosteroid absorption and insufficient safety data in pediatric populations.

Special Populations

Use in special populations such as patients with hepatic or renal impairment has not been extensively studied; caution is advised given potential alterations in systemic metabolism and elimination. Pregnant or breastfeeding women should use Bryhali only if clearly needed and prescribed by a healthcare provider, using the minimum effective amount for the shortest duration. Application to the breasts during breastfeeding is contraindicated to avoid infant exposure via direct contact.

Mechanism Of Action

Halobetasol propionate is a highly potent synthetic corticosteroid belonging to the fluorinated class of glucocorticoids. Its primary molecular mechanism involves binding to intracellular glucocorticoid receptors in skin cells, forming a receptor-steroid complex that translocates into the nucleus. Within the nucleus, the complex interacts with glucocorticoid response elements (GREs) in DNA, modulating gene transcription. It upregulates the expression of anti-inflammatory proteins (e.g., lipocortin-1) and downregulates proinflammatory genes encoding cytokines, enzymes like cyclooxygenase-2, and adhesion molecules, thereby reducing the synthesis and release of inflammatory mediators such as prostaglandins and leukotrienes.

At the cellular and biochemical levels, halobetasol inhibits the migration of inflammatory cells including neutrophils and macrophages to the affected skin, attenuates vasodilation and capillary permeability, and suppresses fibroblast proliferation. This leads to decreased edema, erythema, itching, and scaling observed in psoriatic lesions. Compared to other topical corticosteroids, halobetasol exhibits superior receptor affinity and enhanced lipophilicity, which contributes to its greater potency and skin penetration.

Clinically, halobetasol's potent anti-inflammatory and immunosuppressive effects result in rapid improvement of plaque psoriasis symptoms. However, due to high potency, its use is limited in duration to avoid adverse systemic effects such as HPA axis suppression. Extensive clinical research and trials have demonstrated its efficacy when used appropriately, supporting its approval for moderate to severe plaque psoriasis with lower systemic exposure risks than higher-concentration formulations.

Pharmacological Actions

Potent anti-inflammatory activity by inhibition of multiple inflammatory cytokines and mediators
Immunosuppressive effects reducing infiltration of inflammatory cells in psoriatic plaques
Vasoconstrictive effects decreasing redness and swelling of affected skin
Anti-pruritic properties reducing itching sensations
Reduction of keratinocyte proliferation and normalization of epidermal differentiation
Suppression of immune responses locally in the skin to modulate psoriasis manifestations
Minimal systemic glucocorticoid effects when used as directed due to limited systemic absorption
Reversible suppression of hypothalamic-pituitary-adrenal (HPA) axis at high doses or prolonged use

Therapeutic Clinical Uses

Topical treatment of plaque psoriasis in adults to reduce inflammation, scaling, and pruritus
Management of corticosteroid-responsive dermatoses requiring high-potency topical corticosteroids
Short-term relief of inflammatory skin conditions where less potent steroids are ineffective
Treatment of localized immune-mediated skin disorders with robust anti-inflammatory requirements
Off-label use in certain other dermatoses responsive to corticosteroid therapy under careful medical supervision

Side Or Adverse Effects

Skin burning, stinging, itching, or dryness at application site
Skin thinning (atrophy) and potential for stretch marks with prolonged use
Folliculitis and possible secondary skin infections
Acneiform eruptions and increased hair growth in treated areas
Perioral dermatitis and allergic contact dermatitis
Discoloration or hypopigmentation of treated skin
Development of telangiectasia (spider veins)
Potential for reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with excessive use
High blood sugar levels (hyperglycemia) reported occasionally
Ophthalmic side effects such as cataracts or glaucoma if used near eyes
Systemic corticosteroid side effects in cases of significant absorption including Cushing’s syndrome signs
Irritation, redness, or worsening of skin condition in some patients
Rare allergic reactions including rash and urticaria

Precautions

Avoid application on open wounds, exudative lesions, or irritated skin
Do not apply to skin folds or intertriginous areas to prevent enhanced absorption and irritation
Limit use to recommended duration and dose to avoid systemic corticosteroid effects
Use caution in patients with diabetes due to potential for increased blood glucose levels
Avoid concurrent use with other topical or systemic corticosteroids to prevent additive effects
Monitor for signs of HPA axis suppression in prolonged or extensive use
Do not use near eyes, on face, scalp, groin, or underarms
Discontinue if signs of skin infection or severe irritation appear
Avoid occlusive dressings unless directed by a healthcare professional
Not recommended for pediatric patients under 18 years of age due to risk of systemic absorption
Use cautiously during pregnancy and lactation, weighing benefits vs. risks
Patients with liver disease or adrenal gland disorders require careful evaluation before use

Warnings

Do not use Bryhali for longer than 2 weeks or exceed recommended doses to prevent systemic corticosteroid side effects
Periodic monitoring for hypothalamic-pituitary-adrenal (HPA) axis suppression may be necessary during treatment
Avoid use on broken, infected, or exudative skin lesions
Discontinue use if skin irritation, redness, or worsening of condition occurs
Avoid simultaneous use with other topical or systemic corticosteroids to prevent excessive steroid exposure
Use in children is contraindicated due to increased risk of systemic absorption
Potential to cause Cushing’s syndrome, hyperglycemia, and glucosuria with excessive use
Avoid contact with eyes; immediate rinsing is required if contact occurs
If signs of skin infection develop, treatment with antimicrobials may be required and Bryhali may need to be discontinued
Use with caution in patients with diabetes or other glucose metabolism disorders
Do not cover treated areas with occlusive dressings unless advised
Not recommended during pregnancy and breastfeeding unless clearly needed and prescribed

Contraindications

Hypersensitivity or allergy to halobetasol propionate or any formulation component
Use on skin lesions that are exuding serum or have active skin infections
Application to skin folds, face, groin, axillae, or mucous membranes
Pediatric use in individuals under 18 years of age
Patients with known systemic corticosteroid hypersensitivity
Use in patients with untreated bacterial, viral, or fungal skin infections
Use on widespread or large surface areas exceeding recommended dosage
Patients with Cushing's syndrome or active glucocorticosteroid insufficiency not properly managed
Avoid use in patients with adrenal gland disorders where corticosteroid use may affect endogenous regulation
Do not use on broken skin or open wounds
Contraindicated to use concurrently with other potent topical steroids on the same skin areas

Drug Interactions

Concurrent use with other topical or systemic corticosteroids can have additive effects increasing risk of systemic absorption and adverse effects
May affect blood glucose monitoring and control in diabetic patients due to corticosteroid-induced hyperglycemia
Potential interaction with immunosuppressive drugs altering immune response
Use with caution alongside drugs metabolized by hepatic enzymes, as corticosteroids can modulate enzyme activity
No significant interactions with most systemic drugs when used as directed topically due to minimal systemic absorption
Avoid use with skin irritants or sensitizing agents that can increase skin permeability and absorption
Caution with other medications causing skin thinning or photosensitivity to limit risk of adverse skin effects
Potential additive ocular side effects when used concomitantly with ophthalmic corticosteroids or antiglaucoma agents
Interactions with vaccines are possible; corticosteroids may diminish immune response to live vaccines

Preparations Of The Drug

Bryhali lotion containing halobetasol propionate 0.01% available in 45-gram, 60-gram, and 100-gram aluminum tubes
Formulated as a topical lotion designed for easy application and uniform dispersion over affected skin
Contains inactive ingredients including carbomer copolymer type A and B, diethyl sebacate, edetate disodium, light mineral oil, methylparaben, propylparaben, water, sodium hydroxide, sorbitan monooleate, and sorbitol
Supplied as a prescription-only product for plaque psoriasis treatment
Developed to provide high potency corticosteroid action with a reduced concentration to limit systemic side effects compared to other halobetasol formulations